|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZNF626 |
Gene summary for ZNF626 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZNF626 | Gene ID | 199777 |
| Gene name | zinc finger protein 626 | |
| Gene Alias | ZNF626 | |
| Cytomap | 19p12 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q68DY1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 199777 | ZNF626 | HCC1_Meng | Human | Liver | HCC | 1.67e-57 | 6.86e-02 | 0.0246 |
| 199777 | ZNF626 | cirrhotic2 | Human | Liver | Cirrhotic | 1.31e-02 | 5.21e-02 | 0.0201 |
| 199777 | ZNF626 | HCC1 | Human | Liver | HCC | 2.83e-04 | 7.34e-01 | 0.5336 |
| 199777 | ZNF626 | HCC2 | Human | Liver | HCC | 8.57e-25 | 2.82e+00 | 0.5341 |
| 199777 | ZNF626 | HCC5 | Human | Liver | HCC | 7.60e-15 | 1.21e+00 | 0.4932 |
| 199777 | ZNF626 | S014 | Human | Liver | HCC | 2.15e-02 | 1.95e-01 | 0.2254 |
| 199777 | ZNF626 | male-WTA | Human | Thyroid | PTC | 2.86e-15 | 1.04e-01 | 0.1037 |
| 199777 | ZNF626 | PTC01 | Human | Thyroid | PTC | 3.34e-12 | 1.51e-01 | 0.1899 |
| 199777 | ZNF626 | PTC04 | Human | Thyroid | PTC | 9.19e-13 | 2.15e-01 | 0.1927 |
| 199777 | ZNF626 | PTC05 | Human | Thyroid | PTC | 2.43e-15 | 5.48e-01 | 0.2065 |
| 199777 | ZNF626 | PTC06 | Human | Thyroid | PTC | 6.99e-21 | 5.25e-01 | 0.2057 |
| 199777 | ZNF626 | PTC07 | Human | Thyroid | PTC | 3.64e-32 | 4.22e-01 | 0.2044 |
| 199777 | ZNF626 | ATC12 | Human | Thyroid | ATC | 3.82e-05 | -4.63e-02 | 0.34 |
| 199777 | ZNF626 | ATC13 | Human | Thyroid | ATC | 1.93e-23 | 3.48e-01 | 0.34 |
| 199777 | ZNF626 | ATC4 | Human | Thyroid | ATC | 7.99e-07 | -4.61e-03 | 0.34 |
| 199777 | ZNF626 | ATC5 | Human | Thyroid | ATC | 1.05e-22 | 3.93e-01 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ZNF626 | GC | Breast | ADJ | DNMBP,SRC,ZBTB16, etc. | 2.57e-02 |  |
| ZNF626 | M2MAC | Breast | DCIS | DNMBP,SRC,ZBTB16, etc. | 3.67e-02 |  |
| ZNF626 | DC | Breast | Precancer | DNMBP,SRC,ZBTB16, etc. | 4.70e-02 |  |
| ZNF626 | MSC.PVA | Skin | ADJ | RNF135,MRPL11,ZNF197, etc. | 3.29e-02 |  |
| ZNF626 | FIB | Skin | ADJ | RNF135,MRPL11,ZNF197, etc. | 2.45e-02 | |
| ZNF626 | MSC.MVA | Skin | AK | RNF135,MRPL11,ZNF197, etc. | 4.86e-02 |  |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZNF626 | SNV | Missense_Mutation | c.660N>C | p.Lys220Asn | p.K220N | Q68DY1 | protein_coding | deleterious(0.03) | probably_damaging(0.965) | TCGA-A2-A0EY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| ZNF626 | SNV | Missense_Mutation | novel | c.1583N>A | p.Arg528Lys | p.R528K | Q68DY1 | protein_coding | tolerated_low_confidence(0.11) | benign(0) | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ZNF626 | SNV | Missense_Mutation | novel | c.1297N>A | p.Ala433Thr | p.A433T | Q68DY1 | protein_coding | tolerated(0.07) | possibly_damaging(0.478) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ZNF626 | SNV | Missense_Mutation | c.926N>A | p.Gly309Glu | p.G309E | Q68DY1 | protein_coding | deleterious(0.04) | possibly_damaging(0.525) | TCGA-EW-A1IW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | aromasin | SD | |
| ZNF626 | deletion | Frame_Shift_Del | c.68_74delNNNNNNN | p.Thr23SerfsTer8 | p.T23Sfs*8 | Q68DY1 | protein_coding | TCGA-AN-A0XU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |||
| ZNF626 | SNV | Missense_Mutation | novel | c.305N>A | p.Arg102Lys | p.R102K | Q68DY1 | protein_coding | tolerated(0.16) | benign(0.013) | TCGA-C5-A3HL-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| ZNF626 | SNV | Missense_Mutation | c.364N>C | p.Glu122Gln | p.E122Q | Q68DY1 | protein_coding | deleterious(0.01) | benign(0.285) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD | |
| ZNF626 | SNV | Missense_Mutation | c.353N>A | p.Ile118Lys | p.I118K | Q68DY1 | protein_coding | tolerated(1) | benign(0) | TCGA-FU-A40J-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | carboplatin | CR | |
| ZNF626 | SNV | Missense_Mutation | c.105N>C | p.Glu35Asp | p.E35D | Q68DY1 | protein_coding | deleterious(0.02) | possibly_damaging(0.533) | TCGA-Q1-A73P-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| ZNF626 | SNV | Missense_Mutation | c.532N>C | p.Cys178Arg | p.C178R | Q68DY1 | protein_coding | deleterious(0.03) | benign(0.333) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |